Emerging treatments in parkinson’s disease

European Neurology

Volumn 38, Issue 3, 1997, Pages 175-183

  Albanese, Alberto ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Dopamine; Dopamine agonists; Glutamate; Levodopa; Parkinson s disease; Receptors; Therapy

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; MONOAMINE OXIDASE B INHIBITOR;

ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL RESEARCH; HUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE;

EID: 0030883661     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113371     Document Type: Article

References (79)

1. Mannisto PT, Ulmanen I, Ludstrom K, Tas-kinen J, Tenhunen J, Tilgmann C, Kaakkola S: Characteristics of catechol O-methvllransfer-ase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
2. Nutt JG, Fellman JH: Pharmacokinetics of levodopa. Clin Neuropharmacol 1984:7:35-49.
3. Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE: The pharmacology of Parkinson's disease: Basic aspects and recent advances. Ex-pcrientia 1984:40:1165-1172.
4. Kuruma I, Bartholini G, Tissot R, Pletscher A: The metabolism of L-3-O-mcthyldopa. a precursor of dopa in man. Clin Pharmacol Ther 1971:12:678-682.
5. Nutt JG, Woodward WR, Gancher ST, Merrick D: 3-O-methvldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1973:21:584-588.
6. Muenter MD, Dinapoli RP, Sharpless MS, Tyce GM: 3-O-Mcthyldopa. L-dopa and tryex-yphenidyl in the treatment of Parkinson's disease. Mayo Clin Proc 1973:48:173-183.
7. Wade LA, Katzman R: 3-O-Mcthyldopa and inhibition of L-DOPA at the blood-brain barrier. Life Sci 1975;17:131-136.
8. Reches A, Fahn S: 3-O-Methyldopa blocks dopa metabolism in the rat corpus striatum. Ann Neurol 1982;12:267-271.
9. Ccdarbaum JM, Kult H, McDowell FH: Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology 1988;38:533-536.
10. Fabbrini G, Juncos JL, Mouradian MM, Serrati C. Chase TN: 3-O-Methyldopa and motor fluctuations in Parkinson’s disease. Neurology 1987:37:856-859.
11. Perera R, Isola L, Kaufmann H: Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995:5:211-213.
12. Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S: Catechol-O-Mcthyltransferase activity in human and rat small intestine. Life Sei 1988; 42:2609-2614.
13. Schultz E: Catcchol-O-mcthyl transferase and aromatic L-amino acid decarboxylase activities in human gastrointestinal tissues. Life Sei 1991;49:721-725.
14. Hardebo JE, Owman C: Barrier mechanisms for neurotransmitter monoamines and their precursors in the blood-brain interface. Ann Neurol 1980;8:1-11.
15. Spatz M, Kaneda M, Sumi C, Nagatsu I, Crev-eling CR, Nagatsu T: The presence of catechol-O-methyltransferase activity in separately cultured cercbromicrovascular endothelial and smooth muscle cells. Brain Res 1986:381:363-367.
16. Limousin P, Poliak P, Gervason-Toumier CL, Hommel M, Perret JE: Ro-40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet 1993:341:1605.
17. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A: Effect of entacapone, a COMT inhibitor. on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
18. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A: effect of entacapone. a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994:57:186-189.
19. Limousin P, Poliak P, Pfefen JP, Toumier-Gervason CL, Dubuis R, Perret JE: Acute administration of levodopa-benserazide and tol-capone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995:18:258-265.
20. Davis TL, Roznoski M, Bums RS: Eflfccts of loleaponc in Parkinson’s patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995;10:349-351.
21. Ruottinen HM, Rinne UK: Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
22. Napolitano A, Zürcher G, Daprada M: Effects of tolcapone, a novel catechol-O-methyltrans-ferase inhibitor, on striatal metabolism of I-DOPA and dopamine in rats. Ettr J Pharmacol 1995;273:215-221.
23. Buey PC, Case JT: Tremor: Physiologic mechanism and abolition by surgical means. Arch Neurol Psychiatry (Chicago) 1939:41:721-746.
24. Klemme RM: Surgical treatment of dystonia, paralysis agitans and athetosis. Arch Neurol Psychiatry'(Chicago) 1940;44:926.
25. Hassler R, Reichert T: Indikationen und Lokalisationmethode der gezielten Himoperatio-nen. Nervenarzt 1954:25:441-447.
26. Albanese A: Stereotaxy, the basal ganglial and multidisciplinary approach to Parkinson's disease. Parkinson Magazine 1966;6:1-17.
27. Shannon KM, Goetz CG: Transplantation of adrenal medullar tissue to brain in Parkinson's disease: in Koller WC. Paulson G (eds): Therapy of Parkinson’s disease, ed 2. New York. Dekker, 1995, pp 423-434.
28. Carmichael SW, Wilson RJ, Brimijoin WS, Melton U, Okazaki H, Yaksh TL, Ahlskog JE, Stoddard SL, Tyce GM: Decreased catecholamines in the adrenal medulla of patients with parkinsonism. N Engl J Med 1988:318:254.
29. Madrazo I, León V, Torres C, Aguilera C, Varela G, Alvarez F, Fraga A, Drucker-Colin R, Ostrosky F, Skurovich M: Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson’s disease. N Engl J Med 1988:318:51.
30. Kordower JH, Freeman TB, Snow BJ, Vingcr-hoets FJ, Mufson EJ, Sanberg PR, Hauser RA. Smith DA, Nauert GM. Perl DP. et al: Ncuro-palhological evidence of graft survival and striatal rcinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 1995:332: 1118-1124.
31. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Björklund A. Lindvall O. Langston JW: Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by l-methy!-4-phenyl-l, 2, 3, 6-tctrahy-dropyridinc (MPTP). N Engl J Med 1992:327: 1556-1563.
32. Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Bums LH: Transplanted xenogeneic neural cells in neurodegeneralive disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Natl Med 1995; 1:1189-1194.
33. Aebischer P, Schlucp M, Deglon N, Joseph I-M, Hirt L, Heyd B, Goddard M. Hammang JP, Zum AD, Kato AC, Regli F, Baetge E. Intrathecal delivery of CNTF using encapsulated genetically modified xenogenic cells in amyotrophic lateral sclerosis patients. Natl Med 1996.2: 696-699.
34. Selby G: Stereotactic surgery: in Kollcr WC (ed): Handbook of Parkinson’s Disease, ed 2. New York. Dekker, 1992. pp 529-544.
35. Benabid AL, Poliak P, Louveau A, Henry S, de Rougemont J: Combined (thalamotomy and stimulation) stereotactic surgery of the VIM nucleus for bilateral Parkinson disease. Appl Neurphysiol 1987;50:344-346.
36. Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
37. Scoditti U, Rustichelli P, Calzetti S: Spontaneous hemiballism and disappearance of parkinsonism following contralateral lenticular lacunar infarct. Ital J Neurol Sci 1989; 10:575-577.
38. Bergman H, Wichmann T, DeLong MR: Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990:249: 1436-1438.
39. Laitincn LV, Bergenhcim AT, Ilariz MI: Lek-sell's posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg 1992: 76:53-61.
40. Lozano AM, Lang AE, Galvez-Jimenez N, Mivasaki J, Dul TJ, Hutchinson WD. Dostrov-sky JO: Effect of GPi pallidotomy on motor function in Parkinson’s disease. Lancet 1995; 346:1383-1387.
41. Sutton JP, Couldwell W, Lew MF, Mallory L, Grafton S, DcGiorgio C, Welsh M. Apuzzo ML. Ahmadi J, Waters CH: Ventroposterior medial pallidotomy in patients with advanced Parkinson’s disease. Neurosurgery 1995:36: 1112-1116.
42. Bcnazzouz A. Gross C, Feger J. Boraud T, Bioulac B: Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993:5:382-389.
43. Limousin P, Poliak P, Benazzouz A, Holtman D, Broussolle E, Perret JE, Benabid AL: Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995:10:672-674.
44. Limousin P, Poliak P, Benazzouz A, Hoffman D, Lc Bas J-F. Broussolle E, Perret JE. Benabid AL: Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995:345:91-95.
45. Marcocci L, Maguire JJ, Packer L: Nitccapone: A nitric oxide radical scavenger. Biochem Mol Biol Int 1994:34:531-541.
46. Birkmavcr W, Knoll J, Riederer P. Youdim MBH: Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 1983:19:170-176.
47. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study. J Neural Transnt 1985;64: 113-127.
48. Tetrud JW, Langston JW: The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989:245:519-522.
49. Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989:321:1364-1371.
50. Landau WM: Clinical neuromvthology. IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 1990:40:1337-1339.
51. Lees AJ. Parkinson’s Disease Research Group of the United Kingdom: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 1995;311:1602-1607.
52. Karoum F, Chuang LW, Eisler T, Caine DB, Liebowitz MR, Quitkin FM, Klein DF. Wyatt RJ: Metabolism of deprenyl to amphetamine and mctamphctamine may be responsible for deprenvl's therapeutic benefit: A biochemical assessment. Neurology 1982:32:503-509.
53. Colosimo C, Albancsc A: Boxer disqualified for taking selegiline. Lancet 1995:346:647.
54. Parkinson Study Group: Effect of lazabemide on the progression of disability in early Parkinson’s disease. Ann Neurol 1996:40:99-107.
55. Runge I, Horowski R: Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl. J Neural Transm Park Dis Dement Sect 1991;3:273-283.
56. Clow A, Hussain T, Glover V. Sandler M, Walker M. Dexter D: Pergolide can induce soluble superoxide dismutase in rat striata. J Neural Transnt Gen Sect 1992:90:27-31.
57. Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E: Protective effects of pergolide on dopamine levels in the 6-hydroxydo-pamine-lesioned mouse brain. Arch Int Phar-macodynTher 1995:329:221-230.
58. Bernocchi G, Gherzeli G, Scherini F, Vignola C: Neuroprotective effects of alpha-dihvdroer-gocryptinc against damages in the substantia nigra caused by severe treatment with 1-meth-yl-4-phenyl-l.2, 3.6-tetrahydropyridine. Acta Ncuropathol (Bcrl) 1993:85:404-413.
59. Marzatico F, Cafe C, Taborelli M, Benzi G: Experimental Parkinson's disease in monkeys: Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Neurochem Res 1993:18:1101-1106.
60. Janson AM, Agnati LF, Fuxe K, Cintra A, Sundstrom E, Zini I, Toffano G, Goldstein M: GM1 ganglioside protects against the l-mcthyl-4-phenyl-1, 2.3.6-tetrahydropyridine-induced degencratoin of nigrostriatal dopamine neurons in the black mouse. Acta Phvsiol Scand 1938:132:587-588.
61. Schneider JS, Pope A, Simpson K, Taggart J, Smith MG. DiStefano L: Recovery from experimental parkinsonsim in primates with Gmi gangliosidc treament. Science 1992:256:843-846.
62. Herrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid Y, Luquin MR, Obeso JA, DelRio J: GMI gangliosidc promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 1993:56:965-972.
63. Klockgethcr T, Turski L: Excitatory amino acids and the basal ganglia: Implications for the therapy of Parkinson’s disease. Trends Neurosci 1989;12:285-286.
64. Kupsch A, Loschmann PA. Sauer H. Arnold G, Renner P. Pufal D. Burg M. Wachtel H, Tcn-bruggencate G. Oertel WH: Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and ¡mmunocyiochcmical analyses in black mice. Brain Res 1992:592:74-83.
65. Tabatabaci A, Perry TL, Hansen S, Krieger C: Partial protective effect ofMK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci Lett 1992:141:192-194.
66. Zuddas A, Oberto G, Vagi in i F, Fascetti F, Fornai F, Corsini GU:MK-801 prevents l-methyl-4-phcnyl-1, 2, 3, 6-let rahydropyridine-induced parkinsonism in primates. J Ncurochem 1992: 59:733-739.
67. Brouillet E, Beal MF: NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neurorcport 1993;4:387-390.
68. Chan P, Langston JW, Di Monte DA: MK-80! temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. J Pharmacol Exp Ther 1993:267:1515-1520.
69. Lange KW, Loschmann PA, Sofie E, Burg M, Horowski R, Kalveram K.T, Wachtel H. Ried-erer P: The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunvn Schmiedebergs Arch Pharmacol 1993: 348:586-592.
70. Schwab RS, England A, Poskanzer DC, Young RR: Amantadine in the treatment of Parkinson’s disease. JAMA 1969:208:1168-1170.
71. Stoof JC, Booji J, Drukarch B, Wolters EC: The anti-parkinsonian drug amantadine inhibitis the N-mcthyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a noncompetitive way. Eur J Pharmacol 1992:213: 439-443.
72. Spina MB, Squinto SP, Miller J, Lindsay RM. Hyman C: Brain-derived ncurotrophic factor protects dopamine neurons against 6-hydroxy-dopamine and N-methyl-4-phcnylpyridinium ion toxicity: Involvement of the glutathione system. J Neurochcm 1992:59:99-106.
73. Skaper SD, Negro A, Facci L. Daltoso R: Brain-derived neurotrophic factor selectively rescues mesencephalic dopaminergic neurons from 2, 4, 5-trihydroxyphcnylalanine-induccd injury. J Neurosci Res 1993;34:478-487.
74. Frim DM, Uhler TA, Galpem WR, Beal MF, Breakefield XO, Isacson O: Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-mcthyl-4-phenylpvridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sei USA 194:91:5104-5108.
75. Yoshimoto Y, Lin Q, Collier TJ, Frim DM, Breakefield XO, Bohn MC: Astrocytes rctrovi-rally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson’s disease. Brain Res 1995;691:25-36.
76. Chadi G, Moller A, Rosen L, Janson AM, Agnati LA, Golstein M, Ogren SO, Pettersson RF, Fuxe K: Protective actions of human recombinant basic fibroblast growth factor on MPTP-lcsioned nigrostriatal dopamine neurons after intravcntricular infusion. Exp Brain Res 1993:97:145-158.
77. Otto D, Unsicher K: FGF-2 modulates dopamine and dopamine-related striatal transmitter systems in the intact and MPTP-lesioned mouse. Eur J Neurosci 1993;5:927-932.
78. Beck KD, Valverde J, Alexi T. Poulscn K, Moffat B. Vandlcn RA. Rosenthal A, Hefti F: Mesencephalic dopaminergic neurons protected by GDNF from axolomy-induced degeneration in the adult brain. Nature 1995:373: 339-341.
79. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Iloffcr BJ, Olson L: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335-339.